Quarterly report [Sections 13 or 15(d)]

Commitments and Contingencies - Additional Information (Details)

v3.25.2
Commitments and Contingencies - Additional Information (Details)
6 Months Ended
Oct. 28, 2024
Sep. 08, 2020
Debtinstrument
Jan. 21, 2020
Debtinstrument
Jun. 30, 2025
USD ($)
UsdRln
Nov. 18, 2015
USD ($)
Royalty-Linked Notes          
Other Commitments [Line Items]          
Debt instrument outstanding portion | UsdRln       0.04  
Debt instrument maturity date       Dec. 31, 2045  
Debt instrument price per unit       $ 160.00  
Debt instrument, aggregate potential payment capped rate       4,000  
Royalty-Linked Notes | Private Placement          
Other Commitments [Line Items]          
Number of debt instruments issued | Debtinstrument     2,579,400    
Royalty-Linked Notes | 2020 Rights Offering          
Other Commitments [Line Items]          
Number of debt instruments issued | Debtinstrument   11,000      
Pfizer License Agreement          
Other Commitments [Line Items]          
Regulatory milestone payments upon approval of product         $ 20,000,000
Regulatory and sales milestone deferred payment period 2 years        
Pfizer License Agreement | Minimum          
Other Commitments [Line Items]          
Regulatory and sales milestone payments upon achievement of net sales         250,000,000
Pfizer License Agreement | Maximum          
Other Commitments [Line Items]          
Regulatory and sales milestone payments upon achievement of net sales         $ 1,000,000,000